339539-92-3

Basic information

• Product Name: ONO 7643 FuMarate
• Synonyms: AnaMorelin (FuMarate);ONO 7643 FuMarate;ONO7643 FuMarate;ONO-7643 FuMarate;RC 1291 FuMarate;RC1291 FuMarate;RC-1291 FuMarate;Anamorelin (RC-1291) Fumarate
• CAS NO: 339539-92-3
• Molecular Formula: C35H46N6O7
• Molecular Weight: 662.77574
• Mol File: 339539-92-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ONO 7643 FuMarate(CAS DataBase Reference)
• NIST Chemistry Reference: ONO 7643 FuMarate(339539-92-3)
• EPA Substance Registry System: ONO 7643 FuMarate(339539-92-3)

Safety Data

• Hazardous Substances Data: 339539-92-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
ONO 7643 FuMarate is used as a therapeutic agent for the treatment of dementia and Alzheimer's disease. It is employed for its ability to inhibit phosphodiesterase, thereby potentially increasing the levels of cAMP and cGMP in the brain, which may contribute to neuroprotection and cognitive improvement.
Clinical trials are currently being conducted to evaluate the safety and efficacy of ONO 7643 FuMarate in managing degenerative neurological disorders, highlighting its application in advancing treatments for such conditions.

Upstream product

• 14907-27-8 (R)-(+)-tryptophan methyl ester hydrochloride 
• 339539-90-1 (R,R)-{1-[2-[3-benzyl-3-(N,N',N'-trimethyl-hydrazinocarbonyl)piperidin-1-yl]-1-(1H-indol-3-ylmethyl)-2-oxo-ethylcarbamoyl]-1-methylethyl}carbamic acid tert-butyl ester 
• 159634-94-3 (R)-2-(2-tert-Butoxycarbonylamino-2-methyl-propionylamino)-3-(1H-indol-3-yl)-propionic acid 
• 249921-19-5 Anamorelin 
• 110-17-8 (2E)-but-2-enedioic acid 
• 339539-88-7 1-[(2R)-2-amino-3-(1H-indol-3-yl)propionyl]-(3R)-3-benzylpiperidine-3-carboxylic acid trimethylhydrazide 
• 153-94-6 D-tryptophan 
• 883572-50-7 C₁₆H₂₅N₃O*2ClH 
• 5241-64-5 Boc-D-Trp-OH 
• 883572-59-6 {1-[(1R)-2-[(3R)-3-benzyl-3-(N,N',N'-trimethylhydrazinocarbonyl)piperidin-1-yl]-1-(1H-indol-3-ylmethyl)-2-oxo-ethylcarbamoyl]-1-methylethyl}carbamic acid tert-butyl ester 

Relevant articles and documents

A practical synthesis of the pseudotripeptide RC-1291

The rapid process development of a scaleable synthesis of the pseudotripeptide RC-1291 for preclinical and clinical evaluation is described. By employing a nontraditional N-to-C coupling strategy, the peptide chain of RC-1291 was assembled in high yield, with minimal racemization and in an economical manner by introducing the most expensive component last. A one-pot deprotection/crystallization procedure was developed for the isolation of RC-1291 free base, which afforded the target compound in excellent yield and with a purity of >99.5% without chromatographic purification.

Compound with growth hormone releasing properties

The present invention describes a new compound, 2-Amino-N-[(1R)-2-[(3R)-3-benzyl-3-(N,N′,N′-trimethylhydrazinocarbonyl)piperidin-1-y]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-2-methylpropionamide, having the formula: and pharmaceutically acceptable salts thereof, compositions containing them, and their use for treating medical disorders resulting from a deficiency in growth hormone.